For citations:
Goryainova AY, Stukan AI, Murashko RA, Sharov SV, Lymar EV. Evolution of the CDK4/6 inhibitor abemaciclib: from palliative to adjuvant therapy. Clinical experience with abemaciclib in patients with hormone-receptor-positive, HER2-negative breast cancer. Meditsinskiy sovet = Medical Council. 2022;(9):40-48. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-9-40-48